CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?)
and attended by an outstanding panel of international experts from a wide range of disciplines. Over the course of a half day, speakers gave short (3 minute) presentations, interspersed with fascinating discussions, followed by breakout sessions. We are pleased to include the recordings from those lectures and discussions below. For a summary of the meeting and list of participants please see our recent publication in JNCI.
Written by: Matthew R. Cooperberg, MD, MPH, Professor of Urology, Epidemiology & Biostatistics, Helen Diller Family Chair in Urology, UCSF Department of Urology, University of California, San Francisco, California
Cooperberg, M.R. et al. (2024) ‘When is prostate cancer really cancer?’, JNCI: Journal of the National Cancer Institute [Preprint]. doi:10.1093/jnci/djae200.
Related Content:
Video Presentations: CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?)
CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?)
February 17 2023 Agenda
Agenda
12:00 Lunch
12:20 Introductions
12:27 Welcome and background for this meeting – Scott Eggener
Introduction
12:30 Introduction and rationales for a nomenclature change – Matt Cooperberg
12:33 Reservations about a nomenclature change – Adam Kibel
Viewpoints from outside GU
12:36 When is thyroid cancer not really cancer? – Yuri Nikiforov
12:41 IDLE tumors: what prostate GG1 and breast DCIS can learn from each other – Laura Esserman
12:46 Q&A
Pathology perspectives
12:50 GG1 is not really cancer – Glad Paner
12:53 GG1 is still cancer – Theo van der Kwast
12:56 Where to draw the line? The spatial molecular continuum from “normal” to GG1 to GG2 – Alastair Lamb
12:59 Q&A
Would active surveillance look different if GG1 were not called “cancer”?
1:04 Is grade reclassification the right endpoint to drive treatment on AS? – Dan Lin
1:07 Missed windows of opportunity: when AS breaks down in the real world – Laurie Klotz
1:10 In the MRI era, GG1 is never more than an incidental finding – Declan Murphy
1:13 Which patients are safe for watchful waiting instead of AS? – Caroline Moore
1:16 Q&A
Modeling and statistical perspectives
1:21 What can models teach us about GG1? – Ruth Etzioni
1:24 Are we over-concerned about under-diagnosis of low-volume GG2? – Andrew Vickers
1:27 Q&A
Global perspectives on GG1 and active surveillance
1:32 How would changing nomenclature affect different countries in Europe? – Derya Tilki
1:35 What is the status of low-risk / GG1 prostate cancer in Africa? – Mohamed Jalloh
1:38 Q&A
1:41 Break (10m)
Impact of social determinants of health on GG1 management
1:51 Would there be an impact of nomenclature change in underserved populations? – Quoc Trinh
1:54 Should we manage GG1 differently in Black men? – Kosj Yamoah
1:57 Q&A
Patient viewpoints
2:00 Why nomenclature matters to patients – Howard Wolinsky
2:03 Patient perspective on active surveillance – Leszek Izdebski
2:06 Q&A
Potential impact of a change in nomenclature on policy and advocacy
2:09 Impact of innovative payment models on early stage prostate cancer – CJ Stimson
2:12 The CDC's interest and potential role in redefining GG1 prostate cancer – Ingrid Hall
2:15 Potential impact of nomenclature change on advocacy and funding – Chuck Ryan
2:18 Would a change in nomenclature potentially change primary care screening guidelines? – Tim Wilt
2:21 Q&A Future directions and novel assessments
2:26 Can MRI resolve the nomenclature question? – Hash Ahmed
2:29 Can genomics and/or pathology AI resolve the nomenclature question? – Felix Feng
2:42 Q&A
2:42-2:55: Break, move to breakout rooms
2:55-3:25 Breakout sessions
A. What would the pathology impact of a nomenclature change be?
Room MH-2105 – Moderator: Larry True
B. What would the clinical impact of a nomenclature change be?
Room MH-2106 – Moderator: Marc Dall’Era
C. What would the advocacy and organizational support impact of a nomenclature change be?
Room MH-2107 – Moderator: Chuck Ryan, William Oh
D. What are the potential unintended non-clinical consequences (good and bad) of a nomenclature change?
Room MH-2108 – Moderator: Todd Morgan
E. How can we drive positive change, and what are the policy implications?
Room MH-2109 – Moderator: Stacy Loeb
F. Would a change impact diverse populations differently?
Room MH-2100 – Moderator: Paul Villanti
3:25-3:30: 5m break, return to main room
3:30-4:30: Each breakout group summarizes findings to main group: 5m presentation, 5m discussion
4:30-5:00: General discussion, plans for publication, next steps, and wrap-up